作者: Yamamoto, Shun ; Hamasaki, Hajime ; Ishizaki, Tomotaka ; Oyama, Shintaro ; Mizuno, Satomi ; Tanei, Takafumi ; Sakurai, Takaaki ; Hashida, Miki ; Wakabayashi, Toshihiko ; Suzuki, Takahiro ; Saito, Ryuta

BACKGROUND:

Migraine reduces life quality and work productivity through absenteeism and presenteeism. However, existing paper-based headache diaries have limitations (time-consuming interpretation of heterogeneous entries, inadequate capture of work-related outcomes, etc.). We developed a calendar-style diary with checkmark-only entries to address these shortcomings, while maintaining simplicity for sustained patient adherence. In this single-center retrospective observational study, we assessed whether this format captures important information on patients with migraines attending a specialized headache clinic.

METHODS:

The diary features five key elements: disability quantification (five levels: full-day absence to no productivity loss), headache occurrence time, headache intensity (severe vs. mild to moderate), acute medication intake with an effectiveness assessment, and migraine triggers. Simple diary-derived scores were created to assess absenteeism, presenteeism, headache intensity, and medication effectiveness. Correlation analyses were performed between these scores and validated questionnaires: Work Productivity and Activity Impairment (WPAI) and Migraine Assessment of Current Therapy (Migraine-ACT) for 7- and 31-d datasets, respectively.

RESULTS:

After applying exclusion criteria, 222 and 188 participants were included in the 7- and 31-d datasets, respectively. Diary scores showed meaningful correlations with WPAI domains: absenteeism score with work absenteeism (Kendall's τ = 0.35), presenteeism score with presenteeism (Spearman's ρ = 0.41), overall work impairment (ρ = 0.41), and activity impairment (ρ = 0.36). The number of ineffective medications negatively correlated with the Migraine-ACT score (ρ = -0.27).

CONCLUSIONS:

Our checkmark-only calendar diary systematically monitors productivity loss and treatment response in migraine patients, while maintaining patient adherence through its user-friendly design.

2025-12-01·REVUE NEUROLOGIQUE

Real-world comparison of treatments with antibodies targeting the CGRP pathway or botulinum toxin type A for resistant migraine

Article

作者: Guy, D ; Sickout-Arondo, S ; Delage, N ; Condé, S ; Pereira, B ; Picard, P ; Mongaret, C ; Gardon, L ; Moisset, X

BACKGROUND:

Migraine, particularly in its chronic and treatment-resistant forms, imposes a significant burden on patients. Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway (anti-CGRP mAbs) and onabotulinum toxin type A (BTX-A) have emerged as key preventive treatments for resistant migraine. However, direct comparisons between these therapies remain limited.

OBJECTIVES:

This study aimed to compare the effectiveness of anti-CGRP mAbs and BTX-A in patients with resistant migraine in a real-world setting at a single tertiary care center in France.

METHODS:

A retrospective cohort study was conducted, including 93 patients treated with either anti-CGRP mAbs (n=50) or BTX-A (n=43) for six months. Propensity score matching and inverse probability of treatment weighting (IPTW) were applied to balance baseline differences between groups. The primary outcome was the proportion of patients achieving a ≥50% reduction in monthly headache days.

RESULTS:

After six months, 43% of patients in the anti-CGRP mAbs group and 18% in the BTX-A group achieved a ≥50% reduction in monthly headache days (P=0.003). Using a less stringent 30% threshold, response rates were 54% for anti-CGRP mAbs and 36% for BTX-A (P=0.06). Similar results were observed when the analysis was restricted to chronic migraine patients (n=79). The reduction in monthly headache days was significantly greater in the anti-CGRP mAbs group at both three months (P=0.015) and six months (P=0.022).

CONCLUSION:

Anti-CGRP mAbs demonstrated superior efficacy compared to BTX-A in resistant migraine patients.

2025-12-01·CEPHALALGIA

The interplay between migraine, endometriosis and polycystic ovarian syndrome: A systematic review

Review

作者: Pozo-Rosich, Patricia ; Caronna, Edoardo ; Gómez-Dabó, Laura ; Losa-Puig, Helena ; Jordà-Baleri, Teresa

Background:

Migraine and gynecological conditions, such as endometriosis (EDM) and polycystic ovarian syndrome (PCOS), are highly prevalent among females and appear to influence each other, with a potential shared pathophysiological mechanism. Therefore, this study aims to provide a comprehensive summary of the current evidence regarding the relationship between migraine and EDM/PCOS from a clinical perspective.

Methods:

A systematic review was conducted using four databases (MEDLINE(Pubmed), EMBASE (Elsevier), Web of Science and Cochrane Library) along with searches in the grey literature. The protocol was registered prospectively on the PROSPERO platform (CRD42024628010). The primary search was performed on 4 December 2024. Eligible studies included observational studies that compared two or more groups of females with migraine, EDM and/or PCOS diagnosis. The modified Newcastle-Ottawa Scale was used to assess the quality of the included studies. Data extraction was performed and results systematically analyzed.

Results:

From an initial 408 identified studies, a final selection of 15 was analyzed (14 focused on EDM and 1 on PCOS) with a total of 289,519 individuals included. All selected studies achieved a score of 6 or higher on the mNOS. When comparing females with and without EDM, the prevalence of migraine reached up to 44.7%, with females affected with EDM having up to a five-fold increased risk of developing migraine (adjusted odds ratio = 5.35, 95% confidence interval = 2.11–16.4). When comparing females with and without migraine, a higher prevalence and risk of EDM was observed, with rates reaching 53.4% and an adjusted odds ratio up to 10.5 (95% confidence interval = 2.2–51.4). Mixed findings were found regarding the influence of EDM on migraine characteristics, as well as the impact of migraine in EDM-related symptoms and disease severity. Females with migraine and EDM exhibited higher scores in disability assessment tools (Headache Impact Test-6, 30-item Endometriosis Health Profile), suggesting a greater disease burden. Due to the limited data, no conclusions could be drawn regarding a link between PCOS and migraine.

Conclusions:

Although further high-quality research is required to better understand the underlying mechanisms linking migraine, EDM and PCOS, the current evidence supports a significant association between migraine and endometriosis.Trial Registration: PROSPERO Registration ID: CRD42024628010.

100 项与 Migraine(Kallyope) 相关的药物交易

登录后查看更多信息